Use of the Sustained Pain-Free Plus No Adverse Events Endpoint in Clinical Trials of Triptans in Acute Migraine

被引：0
|
作者：
David W. Dodick
Giorgio Sandrini
Paul Williams
机构：
[1] Mayo Clinic,Department of Neurology
[2] University Center for Adaptive Disorders and Headache,undefined
[3] IRCCS C. Mondino Foundation,undefined
[4] University of Pavia,undefined
[5] PAREXEL International,undefined
来源：
CNS Drugs | 2007年 / 21卷
关键词：
Migraine; Sumatriptan; Zolmitriptan; Rizatriptan; Triptan;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: To assess the relationship between the sustained pain free (SPF) and adverse event (AE) rates associated with six oral serotonin 5-HT1B/1D receptor agonists (triptans) used for the treatment of acute migraine, employing data from a previous meta-analysis (that included almotriptan, eletriptan, naratriptan, rizatriptan, sumatriptan and zolmitriptan, but not frovatriptan) in order to provide a rationale for the use of the rate of patients who are SPF plus no AE (SNAE) as an endpoint in trials of medications for acute migraine.
引用
收藏
页码：73 / 82
页数：9
相关论文
共 50 条
  • [41] Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses From 3 Phase 3 Clinical Trials by Number of Triptans Previously Tried and Failed
    Jensen, C. M.
    Lipton, R. B.
    Blumenfeld, A. M.
    Croop, R.
    Thiry, A.
    L'Italien, G.
    Morris, B.
    Coric, V.
    Goadsby, P. J.
    [J]. CEPHALALGIA, 2021, 41 (1_SUPPL) : 148 - 148
  • [42] Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses From 3 Phase 3 Clinical Trials by Number of Triptans Previously Tried and Failed
    Jensen, C. M.
    Lipton, R. B.
    Blumenfeld, A. M.
    Croop, R.
    Thiry, A.
    L'Italien, G.
    Morris, B.
    Coric, V.
    Goadsby, P. J.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 99 - 100
  • [43] Evaluating the reporting of adverse events in controlled clinical trials conducted in 2010-2015 on migraine drug treatments
    Tfelt-Hansen, Peer
    Lindqvist, Janus Kaufmann
    Thien Phu Do
    [J]. CEPHALALGIA, 2018, 38 (12) : 1885 - 1895
  • [44] Nonmenstrual adverse events during use of implantable contraceptives for women: data from clinical trials
    Brache, V
    Faundes, A
    Alvarez, F
    Cochon, L
    [J]. CONTRACEPTION, 2002, 65 (01) : 63 - 74
  • [45] Reporting of adverse effects in clinical trials should be improved: Lessons from acute postoperative pain
    Edwards, JE
    McQuay, HJ
    Moore, RA
    Collins, SL
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1999, 18 (06) : 427 - 437
  • [46] Use of a theory of expected information for sparse data and adverse events in clinical trials and other biomedical studies
    Robson, B.
    Baek, O. K.
    [J]. INFORMATION SCIENCES, 2024, 680
  • [47] Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double-blind placebo-controlled trial
    Loder, E
    Freitag, FG
    Adelman, J
    Pearlman, S
    Abu-Shakra, S
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (03) : 381 - 389
  • [48] Adverse events in single-arm clinical trials with non-fatal time-to-event efficacy endpoint: from clinical questions to methods for statistical analysis
    Elena Tassistro
    Davide Paolo Bernasconi
    Maria Grazia Valsecchi
    Laura Antolini
    [J]. BMC Medical Research Methodology, 24
  • [49] Adverse events in single-arm clinical trials with non-fatal time-to-event efficacy endpoint: from clinical questions to methods for statistical analysis
    Tassistro, Elena
    Bernasconi, Davide Paolo
    Valsecchi, Maria Grazia
    Antolini, Laura
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2024, 24 (01)
  • [50] Consistency of the Efficacy of Single Use and Repeated Use of M207 (Intracutaneous Microneedle Zolmitriptan) for the Acute Treatment of Migraine; Results for Pain Freedom, Pain Relief, and Sustained Pain Freedom and Pain Relief
    Kellerman, D. J.
    Spierings, E.
    Tepper, S. J.
    Friedman, D., I
    Kudrow, D.
    Berman, G.
    [J]. HEADACHE, 2020, 60 : 29 - 30
12345